Aliases & Classifications for Glioma

Aliases & Descriptions for Glioma:

Name: Glioma 50 29 52 69

Classifications:



Summaries for Glioma

NIH Rare Diseases : 50 glioma refers to a type of brain tumor that develops from the glial cells, which are specialized cells that surround and support neurons (nerve cells) in the brain. it is generally classified based on which type of glial cell is involved in the tumor: astocytoma - tumors that develop from star-shaped glial cells called astrocytes ependymomas - tumors that arise from ependymal cells that line the ventricles of the brain and the center of the spinal cord oligodendrogliomas - tumors that affect the oligodendrocytes the symptoms of glioma vary by type but may include headaches; nausea and vomiting; confusion; personality changes; trouble with balance; vision problems; speech difficulties; and/or seizures. the exact underlying cause is unknown. in most cases, the tumor occurs sporadically in people with no family history of the condition. treatment depends on many factors, including the type, size, stage and location of the tumor, but may include surgery, radiation therapy, chemotherapy and/or targeted therapy. last updated: 7/15/2015

MalaCards based summary : Glioma is related to brain oligodendroglioma and marginal zone b-cell lymphoma. An important gene associated with Glioma is LGI1 (Leucine Rich Glioma Inactivated 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and spinal cord, and related phenotypes are Decreased viability and cellular

Wikipedia : 71 A glioma is a type of tumor that starts in the brain or spine. It is called a glioma because it arises... more...

Related Diseases for Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
id Related Disease Score Top Affiliating Genes
1 brain oligodendroglioma 31.6 IDH1 MDM2 TP53
2 marginal zone b-cell lymphoma 29.4 CDKN2A EGFR MMP2 PTEN TP53 VEGFA
3 bardet-biedl syndrome 29.3 CDKN2A EGFR ERBB2 MMP2 PTEN TP53
4 nasopharyngeal carcinoma 29.2 BAX CDKN2A EGFR IDH1 MDM2 PTEN
5 optic nerve glioma 12.2
6 glioma susceptibility 1 12.2
7 brain stem glioma 12.1
8 childhood brain stem glioma 12.1
9 diffuse intrinsic pontine glioma 12.1
10 glioma susceptibility 2 12.0
11 malignant glioma 12.0
12 glioma susceptibility 9 12.0
13 brain glioma 12.0
14 mixed glioma 12.0
15 chordoid glioma 11.9
16 third ventricle chordoid glioma 11.9
17 optic pathway glioma 11.9
18 subependymal glioma 11.9
19 spinal cord glioma 11.9
20 childhood optic nerve glioma 11.8
21 angiocentric glioma 11.8
22 glioma susceptibility 6 11.7
23 adult brainstem mixed glioma 11.7
24 glioma susceptibility 8 11.7
25 glioma susceptibility 4 11.7
26 adult brain stem glioma 11.7
27 glioma susceptibility 7 11.7
28 glioma susceptibility 5 11.7
29 visual pathway and hypothalamic glioma, childhood 11.6
30 glioblastoma 3 11.4
31 mismatch repair cancer syndrome 11.4
32 astrocytoma 11.2
33 oligoastrocytoma 11.2
34 retinoblastoma 11.1
35 neurofibromatosis 11.1
36 oligodendroglioma 11.1
37 gliosarcoma 11.0
38 pituicytoma 11.0
39 autoimmune encephalitis 11.0
40 nasal glial heterotopia 11.0
41 meningioma, familial 10.7
42 spinal cord ependymoma 10.7
43 malignant ependymoma 10.7
44 myxopapillary ependymoma 10.7
45 anaplastic oligoastrocytoma 10.7
46 legius syndrome 10.7
47 subependymoma 10.7
48 mixed oligodendroglioma-astrocytoma 10.7
49 limbic encephalitis with lgi1 antibodies 10.7
50 paternal uniparental disomy of chromosome 1 10.4 EGFR IDH1 TP53

Graphical network of the top 20 diseases related to Glioma:



Diseases related to Glioma

Symptoms & Phenotypes for Glioma

GenomeRNAi Phenotypes related to Glioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.54 EGFR
2 Decreased viability GR00107-A-1 10.54 PRKCA
3 Decreased viability GR00173-A 10.54 PRKCD
4 Decreased viability GR00221-A-1 10.54 AKT3 CDK6 CDKN2A EGFR PRKCA PRKCD
5 Decreased viability GR00221-A-2 10.54 AKT3 CDK6 PRKCA PRKCD
6 Decreased viability GR00221-A-3 10.54 AKT3 CDKN2A ERBB2
7 Decreased viability GR00221-A-4 10.54 AKT3 CDK6 CDKN2A EGFR PRKCA ERBB2
8 Decreased viability GR00301-A 10.54 AKT3 CDK6
9 Decreased viability GR00342-S-1 10.54 PRKCA
10 Decreased viability GR00342-S-2 10.54 PRKCA
11 Decreased viability GR00342-S-3 10.54 PRKCA
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.87 VEGFA AKT3 EGFR ERBB2 PRKCA PRKCD
13 Decreased substrate adherent cell growth GR00193-A-1 9.73 CDK6
14 Decreased substrate adherent cell growth GR00193-A-2 9.73 AKT3 CDK6 EGFR PRKCD
15 Decreased substrate adherent cell growth GR00193-A-3 9.73 AKT3
16 Apoptosis resistance GR00093-A-0 9.67 CDK6 CDKN2A PRKCD PTEN
17 Increased cell death HMECs cells GR00103-A-0 9.43 EGFR MDM2 PRKCA PRKCD PTEN TP53
18 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT3 EGFR ERBB2 PRKCA

MGI Mouse Phenotypes related to Glioma:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 AKT3 BAX CDK6 CDKN2A EGFR ERBB2
2 growth/size/body region MP:0005378 10.44 AKT3 BAX CDK6 CDKN2A EGFR ERBB2
3 cardiovascular system MP:0005385 10.41 PTEN TP53 VEGFA ACSL5 AKT3 CDK6
4 homeostasis/metabolism MP:0005376 10.39 PRKCD PTEN TP53 VEGFA ACSL5 AKT3
5 hematopoietic system MP:0005397 10.37 MDM2 MMP2 PRKCD PTEN TP53 VEGFA
6 endocrine/exocrine gland MP:0005379 10.35 AKT3 BAX CDK6 CDKN2A EGFR ERBB2
7 mortality/aging MP:0010768 10.35 ERBB2 IDH1 LGI1 MDM2 MMP2 PEG3
8 immune system MP:0005387 10.31 AKT3 BAX CDK6 CDKN2A EGFR IDH1
9 neoplasm MP:0002006 10.25 GLIPR1 MDM2 MMP2 PRKCA PTEN TP53
10 nervous system MP:0003631 10.25 CDKN2A EGFR ERBB2 LGI1 MDM2 MMP2
11 muscle MP:0005369 10.23 BAX CDK6 CDKN2A EGFR ERBB2 MDM2
12 embryo MP:0005380 10.19 CDK6 CDKN2A EGFR ERBB2 MDM2 PTEN
13 integument MP:0010771 10.18 CDKN2A EGFR ERBB2 LGI1 MDM2 PRKCA
14 liver/biliary system MP:0005370 10.1 CDK6 CDKN2A EGFR MDM2 PRKCD PTEN
15 limbs/digits/tail MP:0005371 10.05 PTEN TP53 VEGFA BAX EGFR ERBB2
16 reproductive system MP:0005389 10 AKT3 BAX CDK6 CDKN2A EGFR ERBB2
17 renal/urinary system MP:0005367 9.87 BAX EGFR MDM2 PRKCD PTEN TP53
18 pigmentation MP:0001186 9.85 CDKN2A EGFR LGI1 MDM2 PTEN TP53
19 respiratory system MP:0005388 9.81 BAX CDKN2A EGFR ERBB2 IDH1 MMP2
20 skeleton MP:0005390 9.73 ACSL5 BAX CDKN2A EGFR ERBB2 IDH1
21 vision/eye MP:0005391 9.28 BAX CDKN2A EGFR LGI1 MMP2 PTEN

Drugs & Therapeutics for Glioma

Drugs for Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 652)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
7
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
8
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
9
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
10
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
11
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
12 Piracetam Approved Phase 4,Phase 2 7491-74-9
13
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
14
Benzocaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1994-09-7, 94-09-7 2337
15
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
16
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
18 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
21 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
26 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
27 Etiracetam Phase 4,Phase 1,Phase 2
28 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2
32 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
39 GABA Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Neuroprotective Agents Phase 4,Phase 2,Phase 1
41 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Tranquilizing Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Anti-Anxiety Agents Phase 4,Phase 2
44 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 1
45 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
46 Antimanic Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
48 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
49 Glutamic Acid Nutraceutical Phase 4
50
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 1869)
id Name Status NCT ID Phase
1 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
2 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
3 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
4 Perampanel in Seizure Patients With Primary Glial Brain Tumors Recruiting NCT02363933 Phase 4
5 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4
6 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
7 Seizure Treatment in Glioma Not yet recruiting NCT03048084 Phase 4
8 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4
9 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
10 Cognitive Rehabilitation of Glioma Patients Unknown status NCT00256425 Phase 3
11 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
12 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3
13 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3
14 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
15 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
16 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3
17 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
18 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
19 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3
20 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Unknown status NCT01149109 Phase 3
21 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3
22 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3
23 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3
24 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3
25 Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Completed NCT01635140 Phase 3
26 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3
27 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3
28 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
29 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3
30 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
31 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
32 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3
33 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3
34 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3
35 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3
36 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3
37 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3
38 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3
39 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3
40 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3
41 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
42 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
43 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
44 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3
45 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3
46 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3
47 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed NCT00085735 Phase 3
48 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3
49 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
50 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3

Search NIH Clinical Center for Glioma

Genetic Tests for Glioma

Genetic tests related to Glioma:

id Genetic test Affiliating Genes
1 Glioma 29

Anatomical Context for Glioma

MalaCards organs/tissues related to Glioma:

39
Brain, Endothelial, Spinal Cord, T Cells, Bone, Monocytes, Thyroid

Publications for Glioma

Articles related to Glioma:

(show top 50) (show all 6424)
id Title Authors Year
1
DNA methylation-mediated caspase-8 downregulation is associated with anti-apoptotic activity and human malignant glioma grade. ( 28204824 )
2017
2
Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. ( 28088075 )
2017
3
Lactoferrin-coated polysaccharide nanoparticles based on chitosan hydrochloride/hyaluronic acid/PEG for treating brain glioma. ( 27987946 )
2017
4
Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis. ( 28083786 )
2017
5
Tetrandrine inhibits glioma stem-like cells by repressing I^-catenin expression. ( 27909720 )
2017
6
Predictors and mechanisms of epilepsy occurrence in cerebral gliomas: What to look for in clinicopathology. ( 28087392 )
2017
7
Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma. ( 27050560 )
2017
8
Validation of an established prognostic score after re-irradiation of recurrent glioma. ( 28075197 )
2017
9
MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in high-grade glioma. ( 27837373 )
2017
10
High expression of RAB43 predicts poor prognosis and is associated with epithelial-mesenchymal transition in gliomas. ( 28075478 )
2017
11
Lipoprotein lipase and phospholipid transfer protein overexpression in human glioma cells and their effect on cell growth, apoptosis, and migration. ( 27864281 )
2017
12
Silencing of Forkhead box D1 inhibits proliferation and migration in glioma cells. ( 28075458 )
2017
13
Prosopagnosia Induced by a Left Anterior Temporal lobectomy Following a Right Temporo-occipital Resection in a Multicentric Diffuse Low-Grade Glioma. ( 27756661 )
2017
14
Knockdown of linc-OIP5 inhibits proliferation and migration of glioma cells through down-regulation of YAP-NOTCH signaling pathway. ( 28189759 )
2017
15
Unusual presentation of an intracranial hemangiopericytoma as a cystic intraparenchymal mass lesion closely mimicking a glioma. ( 28084283 )
2017
16
MicroRNAa8921 promotes migration and invasion of glioma cells via activation of Sox2 and I^a89catenin signaling. ( 27909726 )
2017
17
Overexpression of Transforming Acidic Coiled Coila89Containing Protein 3 Reflects Malignant Characteristics and Poor Prognosis of Glioma. ( 28273854 )
2017
18
Overexpression of CPEB4 in glioma indicates a poor prognosis by promoting cell migration and invasion. ( 28381179 )
2017
19
Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma. ( 28349823 )
2017
20
PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186. ( 28351322 )
2017
21
MicroRNA-302a targets GAB2 to suppress cell proliferation, migration and invasion of glioma. ( 28000880 )
2017
22
Canine spinal cord glioma. ( 28074710 )
2017
23
Assessing light-independent effects of hypericin on cell viability, ultrastructure and metabolism in human glioma and endothelial cells. ( 28087315 )
2017
24
Intra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imaging. ( 28078511 )
2017
25
The effects of CD147 on the cell proliferation, apoptosis, invasion, and angiogenesis in glioma. ( 27761842 )
2017
26
Membrane-depolarizing channel blockers induce selective glioma cell death by impairing nutrient transport and unfolded protein/amino acid responses. ( 28087597 )
2017
27
Neuroglobin functions as a prognostic marker and promotes the tumor growth of glioma via suppressing apoptosis. ( 28103511 )
2017
28
Overexpression of SCUBE2 Inhibits Proliferation, Migration, and Invasion in Glioma Cells. ( 27697090 )
2017
29
Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status. ( 28091987 )
2017
30
RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells. ( 28076755 )
2017
31
Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma. ( 27553586 )
2017
32
Forkhead box P3 regulates ARHGAP15 expression and affects migration of glioma cells through the Rac1 signaling pathway. ( 27862679 )
2017
33
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth. ( 28061453 )
2017
34
Shift of microRNA profile upon glioma cell migration using patient-derived spheroids and serum-free conditions. ( 28091986 )
2017
35
The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis. ( 27629767 )
2017
36
Long non-coding RNA ZFAS1 is an unfavourable prognostic factor and promotes glioma cell progression by activation of the Notch signaling pathway. ( 28081466 )
2017
37
Silencing of the long non-coding RNA NEAT1 suppresses glioma stem-like properties through modulation of the miR-107/CDK6 pathway. ( 27878295 )
2017
38
Imaging mass spectrometry identifies prognostic ganglioside species in rodent intracranial transplants of glioma and medulloblastoma. ( 28463983 )
2017
39
Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133. ( 27721007 )
2017
40
MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3. ( 28260020 )
2017
41
MicroRNA-194 represses glioma cell epitheliala89toa89mesenchymal transition by targeting Bmi1. ( 28098896 )
2017
42
Elevated IQGAP1 and CDC42 levels correlate with tumor malignancy of human glioma. ( 28035419 )
2017
43
Interaction between transcription factors PAX6/PAX6-5a and specific members of miR-183-96-182 cluster, may contribute to glioma progression in glioblastoma cell lines. ( 28184912 )
2017
44
Rapid and fulminant leptomeningeal spread following radiotherapy in diffuse intrinsic pontine glioma. ( 28084680 )
2017
45
(11)C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma. ( 28078638 )
2017
46
The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells. ( 28423669 )
2017
47
Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells. ( 28362995 )
2017
48
Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway. ( 28081224 )
2017
49
Hypoxia-induced production of peptidylarginine deiminases and citrullinated proteins in malignant glioma cells. ( 27818200 )
2017
50
Inhibition of Beclin-1-Mediated Autophagy by MicroRNA-17-5p Enhanced the Radiosensitivity of Glioma Cells. ( 28081732 )
2017

Variations for Glioma

Copy number variations for Glioma from CNVD:

7 (show top 50) (show all 1065)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13321 2 208809197 208828051 Copy number IDH1 Glioma
2 14132 1 10403401 10408000 Deletion Glioma
3 14198 1 105227801 105232100 Deletion Glioma
4 15004 1 111800000 116100000 Deletion Glioma
5 15199 1 113411001 113417300 Deletion BC037540 Glioma
6 15250 1 113839501 113849000 Deletion Glioma
7 15641 1 117679901 117685200 Deletion Glioma
8 15695 1 118394101 118397900 Deletion Glioma
9 19119 1 148648801 148652600 Deletion Glioma
10 19806 1 151480801 151485400 Deletion Glioma
11 20843 1 154791301 154797500 Deletion IQGAP3 Glioma
12 21174 1 157132201 157138600 Deletion Glioma
13 21291 1 157913501 157918300 Deletion Glioma
14 21685 1 160317401 160321200 Deletion Glioma
15 23692 1 173061201 173070300 Deletion Glioma
16 24042 1 174742901 174746800 Deletion Glioma
17 24302 1 178448601 178452400 Deletion Glioma
18 25156 1 185029601 185033600 Deletion Glioma
19 25220 1 185729601 185734900 Deletion Glioma
20 25241 1 185980701 185991100 Deletion Glioma
21 25290 1 186804101 186808700 Deletion Glioma
22 25655 1 192615401 192619700 Deletion Glioma
23 26024 1 195765301 195771800 Deletion Glioma
24 26054 1 196268601 196275300 Deletion Glioma
25 26178 1 197703301 197708700 Deletion Glioma
26 26883 1 20368201 20372100 Deletion PLA2G2C Glioma
27 26979 1 204445801 204451500 Deletion Glioma
28 27209 1 205357001 205361800 Deletion Glioma
29 27636 1 210535701 210541200 Deletion Glioma
30 27909 1 215522601 215526900 Deletion Glioma
31 27938 1 216247201 216257200 Deletion Glioma
32 27948 1 216310301 216315100 Deletion Glioma
33 28054 1 217987801 217992100 Deletion Glioma
34 28169 1 219443901 219451100 Deletion Glioma
35 28238 1 220438701 220448900 Deletion Glioma
36 28860 1 226089101 226092600 Deletion Glioma
37 29433 1 232027401 232031900 Deletion Glioma
38 29707 1 234613701 234620000 Deletion Glioma
39 29744 1 234984301 234988400 Deletion ACTN2 Glioma
40 29950 1 238457901 238463400 Deletion Glioma
41 29974 1 238682401 238685500 Deletion Glioma
42 30033 1 239425501 239429300 Deletion Glioma
43 30273 1 241490101 241494000 Deletion Glioma
44 30527 1 244220301 244224400 Deletion Glioma
45 30564 1 244503701 244507900 Deletion Glioma
46 30805 1 246116501 246126100 Deletion OR2W3 Glioma
47 31058 1 25029301 25036000 Deletion Glioma
48 31536 1 28129101 28135200 Deletion SMPDL3B Glioma
49 31728 1 30200000 32400000 Deletion Glioma
50 33111 1 42513801 42517800 Deletion FOXJ3 Glioma

Expression for Glioma

Search GEO for disease gene expression data for Glioma.

Pathways for Glioma

Pathways related to Glioma according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 AKT3 EGFR ERBB2 GLIPR1 IDH1 MDM2
2
Show member pathways
13.96 AKT3 BAX CDK6 CDKN2A EGFR ERBB2
3
Show member pathways
13.94 AKT3 BAX CDKN2A EGFR MDM2 MMP2
4
Show member pathways
13.91 AKT3 BAX CDKN2A EGFR ERBB2 MDM2
5
Show member pathways
13.82 AKT3 CDKN2A EGFR ERBB2 MDM2 MMP2
6
Show member pathways
13.51 AKT3 BAX EGFR ERBB2 MDM2 PRKCA
7
Show member pathways
13.38 AKT3 BAX EGFR ERBB2 PRKCA PRKCD
8
Show member pathways
13.28 AKT3 BAX EGFR ERBB2 PRKCA PRKCD
9
Show member pathways
13.16 AKT3 EGFR MDM2 PRKCA PRKCD PTEN
10
Show member pathways
13.05 AKT3 BAX CDKN2A MDM2 PTEN TP53
11
Show member pathways
13 AKT3 BAX CDK6 PRKCA PTEN TP53
12
Show member pathways
13 AKT3 CDK6 EGFR ERBB2 PRKCA PTEN
13
Show member pathways
12.98 AKT3 CDKN2A EGFR PRKCA PRKCD VEGFA
14
Show member pathways
12.96 AKT3 EGFR ERBB2 PRKCA PRKCD PTEN
15
Show member pathways
12.9 AKT3 EGFR MMP2 PRKCA PRKCD PTEN
16
Show member pathways
12.9 AKT3 BAX ERBB2 PRKCA PRKCD PTEN
17
Show member pathways
12.83 AKT3 EGFR ERBB2 MDM2 PTEN TP53
18 12.79 AKT3 EGFR PRKCA PRKCD TP53
19
Show member pathways
12.75 AKT3 MMP2 PRKCA PRKCD VEGFA
20
Show member pathways
12.7 AKT3 BAX EGFR ERBB2 MMP2 TP53
21 12.67 AKT3 CDK6 EGFR MDM2 PRKCA PTEN
22
Show member pathways
12.66 AKT3 CDK6 CDKN2A MDM2 TP53
23
Show member pathways
12.63 AKT3 BAX CDK6 CDKN2A EGFR ERBB2
24
Show member pathways
12.61 AKT3 EGFR ERBB2 PRKCA PTEN TP53
25
Show member pathways
12.61 AKT3 EGFR ERBB2 MDM2 MMP2 PRKCA
26
Show member pathways
12.59 AKT3 BAX ERBB2 PRKCD PTEN
27 12.53 AKT3 CDK6 PRKCA PRKCD TP53
28
Show member pathways
12.5 AKT3 BAX MDM2 PTEN TP53
29
Show member pathways
12.5 AKT3 BAX EGFR ERBB2 MDM2 PRKCA
30 12.5 CDK6 CDKN2A EGFR ERBB2 MDM2 PRKCA
31
Show member pathways
12.48 BAX CDK6 CDKN2A MDM2 PTEN TP53
32
Show member pathways
12.47 AKT3 PRKCA PRKCD VEGFA
33
Show member pathways
12.45 AKT3 PRKCA PRKCD PTEN
34
Show member pathways
12.45 AKT3 BAX EGFR ERBB2 MDM2 PTEN
35 12.43 CDK6 CDKN2A MDM2 TP53
36
Show member pathways
12.43 EGFR PRKCA PRKCD VEGFA
37
Show member pathways
12.42 AKT3 EGFR ERBB2 MDM2 PRKCA TP53
38
Show member pathways
12.4 AKT3 PRKCA PRKCD PTEN
39 12.4 BAX CDK6 CDKN2A MDM2 TP53
40
Show member pathways
12.4 AKT3 EGFR ERBB2 PRKCA PRKCD
41
Show member pathways
12.39 AKT3 EGFR ERBB2 PRKCA
42
Show member pathways
12.37 AKT3 BAX MDM2 PTEN TP53
43
Show member pathways
12.35 AKT3 EGFR PRKCA PRKCD PTEN VEGFA
44
Show member pathways
12.33 PRKCA PRKCD TP53 VEGFA
45 12.31 AKT3 EGFR ERBB2 MDM2 MMP2 PRKCA
46 12.3 BAX EGFR MMP2 TP53 VEGFA
47
Show member pathways
12.3 AKT3 EGFR ERBB2 MDM2 PTEN TP53
48 12.29 EGFR ERBB2 PRKCA PRKCD PTEN
49 12.26 BAX EGFR MDM2 PTEN TP53 VEGFA
50
Show member pathways
12.25 AKT3 EGFR ERBB2 PRKCA PTEN

GO Terms for Glioma

Cellular components related to Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.56 ACSL5 BAX CDKN2A IDH1 MMP2 PRKCA
2 cytoplasm GO:0005737 9.5 AKT3 BAX CDK6 CDKN2A EGFR ERBB2

Biological processes related to Glioma according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.99 AKT3 CDK6 EGFR ERBB2 PRKCA PRKCD
2 negative regulation of cell proliferation GO:0008285 9.97 BAX CDK6 CDKN2A PTEN TP53
3 angiogenesis GO:0001525 9.89 MMP2 PRKCA PTEN VEGFA
4 phosphorylation GO:0016310 9.8 AKT3 CDK6 CDKN2A EGFR ERBB2 PRKCA
5 positive regulation of cell growth GO:0030307 9.78 EGFR ERBB2 LGI1
6 positive regulation of epithelial cell proliferation GO:0050679 9.74 EGFR ERBB2 VEGFA
7 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.73 BAX MDM2 TP53
8 positive regulation of MAP kinase activity GO:0043406 9.72 EGFR ERBB2 VEGFA
9 phosphatidylinositol-mediated signaling GO:0048015 9.71 EGFR ERBB2 PTEN TP53
10 cellular response to growth factor stimulus GO:0071363 9.7 EGFR ERBB2 MDM2
11 apoptotic process GO:0006915 9.7 BAX CDKN2A PEG3 PRKCA PRKCD PTEN
12 positive regulation of cell adhesion GO:0045785 9.67 ERBB2 PRKCA VEGFA
13 ERBB2 signaling pathway GO:0038128 9.63 EGFR ERBB2 PRKCA
14 cellular response to hypoxia GO:0071456 9.62 MDM2 PTEN TP53 VEGFA
15 replicative senescence GO:0090399 9.61 CDKN2A TP53
16 positive regulation of superoxide anion generation GO:0032930 9.58 EGFR PRKCD
17 negative regulation of glial cell apoptotic process GO:0034351 9.54 PRKCA PRKCD
18 regulation of cell motility GO:2000145 9.54 CDK6 EGFR ERBB2
19 negative regulation of immature T cell proliferation in thymus GO:0033088 9.48 CDKN2A ERBB2
20 cellular response to actinomycin D GO:0072717 9.43 MDM2 TP53
21 cell proliferation GO:0008283 9.43 BAX EGFR ERBB2 LGI1 PTEN TP53
22 positive regulation of gene expression GO:0010628 9.1 CDK6 ERBB2 MDM2 PTEN TP53 VEGFA
23 intracellular signal transduction GO:0035556 10 AKT3 EGFR ERBB2 PRKCA PRKCD

Molecular functions related to Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.92 ACSL5 AKT3 CDK6 EGFR ERBB2 PRKCA
2 protein heterodimerization activity GO:0046982 9.85 BAX EGFR ERBB2 TP53 VEGFA
3 protein kinase binding GO:0019901 9.77 CDKN2A EGFR PRKCD PTEN TP53
4 protein kinase activity GO:0004672 9.73 AKT3 CDK6 EGFR ERBB2 PRKCA PRKCD
5 identical protein binding GO:0042802 9.7 BAX EGFR ERBB2 MDM2 PTEN TP53
6 protein phosphatase binding GO:0019903 9.61 EGFR ERBB2 TP53
7 kinase activity GO:0016301 9.5 AKT3 CDK6 CDKN2A EGFR ERBB2 PRKCA
8 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 EGFR ERBB2
9 enzyme binding GO:0019899 9.1 EGFR MDM2 PRKCA PRKCD PTEN TP53

Sources for Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....